US › Healthcare

Amylyx Pharmaceuticals Inc (AMLX)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$21.87+8.43%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-41.3M
Profit YoY
-15.0%
EPS
$-0.37
EPS estimate
$-0.34

EPS came in at -0.37 against a street estimate of -0.34 — a miss of 8.8%.

Key statistics

Market cap
$2.24B
Forward P/E
2.8
P/B
8.27
Book value
$2.46
EPS (TTM)
$-1.48
52-week high
$22.28
52-week low
$7.48
50-day MA
$16.42
200-day MA
$14.83
Beta
-0.20

Analyst view

Analysts rate Amylyx Pharmaceuticals Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $24.89.

Shareholding

Insiders
7.89%
Institutions
105.42%

Largest institutional holders

FundStake
FMR Inc14.96%
BlackRock Inc7.94%
Perceptive Advisors LLC7.45%
TCG Crossover Management, LLC5.62%
Vanguard Group Inc5.22%
COMMODORE CAPITAL LP5.08%
HHG PLC4.48%
Saturn V Capital Management LLC3.91%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Amylyx Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.